Finally, the impact of prior inotuzumab ozogamicin (INO), an anti‐CD22 monoclonal antibody–calicheamicin conjugate, was not evaluated in this study as INO was approved for the treatment of adults with r/r BCP ALL after the studies reported here.21 This evidence concerns the gene CD22 and acute lymphoblastic leukemia.